Plan for US Policy Uncertainty to Increase Global Commercial Opportunity for Launch Assets
As US drug pricing policy accelerates toward Most Favored Nation (MFN) benchmarks, biopharma companies must rethink global launch strategies to manage risk, maintain access and unlock commercial opportunity across markets.
With the US reviving Most Favored Nation (MFN) pricing and introducing new tariff threats, pharmaceutical manufacturers face critical decisions about global pricing, launch sequencing and market access strategy. This analysis explores real-world revenue exposure, strategic risks for SMIDs and large pharma, and how to turn policy disruption into a competitive advantage.
Download the full report to:
- Analyze how MFN policy changes may impact global product launches and pricing strategies
- Evaluate US vs. ex-US revenue exposure across therapeutic areas and product types
- Understand why small and mid-sized pharma may face outsized risks
- Explore adaptive strategies to mitigate MFN risk and optimize launch sequencing
- Get ahead of evolving payer expectations and global reference pricing trends
Fill out the form to download the full MFN drug pricing impact report to guide your global launch strategy.
Related Content
Looking for exclusive insight?
